PhD in Genetic Engineering, Kyungpook National University (2008)
Senior Researcher, Patent Information Promotion Center (2012-Present)
Biologics (Cellular and Gene Therapy, Antibody) and In vitro Diagnostics
Honors & Awards
Cellular Immunotherapy - IP Trends and Issues
In 2017, the FDA approved Kymriah(Novartis) and Yescarta(Kite Pharma/Gilead) for the CAR-T cell therapy.
The CAR-T cell therapy is recognized as innovative technology which converged the field of gene therapy and immune cell therapy. With the success of the CAR-T cell therapy, the anticancer immunotherapy is expected to be further advanced.
In this presentation, I would like to summarize the patent application trends and recent IP issues related to CAR-T cell which is a representative treatment in cellular immunotherapy.